Via The New York Times: Sanofi Says Dengue Vaccine Succeeds in Late-Stage Trial. Excerpt:
The French pharmaceutical company Sanofi said on Monday that its experimental vaccine for dengue fever had succeeded in its first late-stage clinical trial. The results could help pave the way for introduction of the first vaccine to prevent a disease that afflicts as many as 100 million people a year.
Sanofi said the vaccine reduced the incidence of dengue fever by 56 percent in a trial involving more than 10,000 children in Southeast Asia. It said that was a big enough reduction to achieve the primary goal of the study.
A news release announcing the results did not contain much more detail. The company said it was still analyzing the data and would present more details at a medical conference and in a peer-reviewed publication later this year.
“This achievement is the result of more than 20 years of work in the field of dengue, collaborating with investigators, volunteers, authorities, scientific experts and international organizations,” Olivier Charmeil, chief executive of Sanofi Pasteur, the vaccine arm of the company, said in a statement. “Our goal is to make dengue the next vaccine-preventable disease.”
Dengue fever is caused by a virus transmitted by mosquitoes and affects people mainly in tropical and subtropical areas. While not a big problem in the United States, the Florida Keys did have its first cases in decades in 2009.
The disease, also known as breakbone fever, can cause severe fever and intense joint and muscle pain. Serious cases can cause hemorrhagic fever, which is marked by bleeding and shock. These can be fatal, especially to children.